Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Devegowda, Vani N. | - |
dc.contributor.author | Kim, Jung Hyun | - |
dc.contributor.author | Han, Ki-Cheol | - |
dc.contributor.author | Yang, Eun Gyeong | - |
dc.contributor.author | Choo, Hyunah | - |
dc.contributor.author | Pae, Ae Nim | - |
dc.contributor.author | Nam, Ghilsoo | - |
dc.contributor.author | Choi, Kyung Il | - |
dc.date.accessioned | 2024-01-20T19:34:16Z | - |
dc.date.available | 2024-01-20T19:34:16Z | - |
dc.date.created | 2021-09-02 | - |
dc.date.issued | 2010-03-01 | - |
dc.identifier.issn | 0960-894X | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/131645 | - |
dc.description.abstract | A novel series of 3,5,6-trisubstituted pyrazolo[4,3-d] pyrimidin-7-one derivatives, especially 6-N-arylcarboxamidopyrazolo[4,3-d]pyrimidin-7-ones were synthesized and evaluated for their in vitro anticancer activities against various human cancer cell lines. The inhibitory activities for several kinases have also been tested. The prepared compounds library exhibited significant anticancer activity towards HT-29 colon and DU-145 prostate cancer cell lines. The structure-activity relationships of the 6-N-arylcarboxamidopyrazolo[4,3-d] pyrimidin-7-one scaffold at R-1, R-2 and R-3 have been elucidated. Among the synthesized compounds, 12b was the most active compound with GI(50) value of 0.44 mu M and 1.07 mu M against HT-29 and DU-145 cell lines, respectively, and 13a was the most selective compound towards colon cancer cell line. (C) 2010 Published by Elsevier Ltd. | - |
dc.language | English | - |
dc.publisher | Pergamon Press Ltd. | - |
dc.subject | CANCER-RESEARCH | - |
dc.subject | INHIBITORS | - |
dc.subject | PHOSPHODIESTERASE-5 | - |
dc.title | Novel 6-N-arylcarboxamidopyrazolo[4,3-d]pyrimidin-7-one derivatives as potential anti-cancer agents | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.bmcl.2010.01.029 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | Bioorganic & Medicinal Chemistry Letters, v.20, no.5, pp.1630 - 1633 | - |
dc.citation.title | Bioorganic & Medicinal Chemistry Letters | - |
dc.citation.volume | 20 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1630 | - |
dc.citation.endPage | 1633 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000274714600037 | - |
dc.identifier.scopusid | 2-s2.0-76649107345 | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | CANCER-RESEARCH | - |
dc.subject.keywordPlus | INHIBITORS | - |
dc.subject.keywordPlus | PHOSPHODIESTERASE-5 | - |
dc.subject.keywordAuthor | 6-N-Arylcarboxamidopyrazolo[4,3-d]pyrimidin-7-one | - |
dc.subject.keywordAuthor | Anticancer activity | - |
dc.subject.keywordAuthor | Structure-activity relationship | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.